Cipla announces successful completion of Phase-3 clinical study of GSKs Advair Diskus; stock up 3%

The product is indicated to treat asthma in patients 4 years and older as a twice-daily prescription medicine and in long term to treat chronic obstructive pulmonary disease (COPD), including chronic bronchitis, emphysema, or both, for better breathing and fewer flare-ups.

from India Infoline News Service https://ift.tt/344Yi78